Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) shares crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $4.42 and traded as low as $2.76. Rocket Pharmaceuticals shares last traded at $2.81, with a volume of 2,447,394 shares.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on RCKT shares. The Goldman Sachs Group downgraded Rocket Pharmaceuticals from a "neutral" rating to a "sell" rating in a research note on Wednesday, May 28th. Evercore ISI lowered shares of Rocket Pharmaceuticals from an "outperform" rating to an "in-line" rating and set a $5.00 price objective on the stock. in a research note on Friday, May 30th. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 target price (down previously from $37.00) on shares of Rocket Pharmaceuticals in a research note on Wednesday, May 28th. BMO Capital Markets dropped their price objective on Rocket Pharmaceuticals from $30.00 to $8.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 28th. Finally, Scotiabank decreased their price objective on Rocket Pharmaceuticals from $51.00 to $19.00 and set a "sector outperform" rating for the company in a research report on Wednesday, May 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $18.60.
Get Our Latest Report on RCKT
Rocket Pharmaceuticals Stock Up 8.1%
The stock's 50-day moving average price is $4.24 and its two-hundred day moving average price is $7.45. The company has a current ratio of 9.19, a quick ratio of 9.19 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $341.73 million, a P/E ratio of -1.22 and a beta of 0.67.
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.02. During the same period in the previous year, the company earned ($0.66) earnings per share. As a group, research analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.
Insider Activity
In other Rocket Pharmaceuticals news, CEO Gaurav Shah bought 20,000 shares of the stock in a transaction on Thursday, April 10th. The shares were acquired at an average price of $5.08 per share, with a total value of $101,600.00. Following the acquisition, the chief executive officer directly owned 792,680 shares of the company's stock, valued at $4,026,814.40. The trade was a 2.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 24.76% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Rocket Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of Rocket Pharmaceuticals by 24.5% in the fourth quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company's stock worth $175,919,000 after purchasing an additional 2,753,033 shares during the last quarter. Suvretta Capital Management LLC purchased a new position in Rocket Pharmaceuticals in the 4th quarter worth approximately $32,267,000. Janus Henderson Group PLC increased its holdings in shares of Rocket Pharmaceuticals by 111.0% in the 4th quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company's stock worth $50,343,000 after buying an additional 2,106,699 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Rocket Pharmaceuticals by 3,163.9% in the 4th quarter. Point72 Asset Management L.P. now owns 1,569,823 shares of the biotechnology company's stock worth $19,733,000 after buying an additional 1,521,727 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in shares of Rocket Pharmaceuticals during the 4th quarter valued at $18,428,000. 98.39% of the stock is owned by hedge funds and other institutional investors.
Rocket Pharmaceuticals Company Profile
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Featured Stories
Before you consider Rocket Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.
While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.